Researchers have developed a novel digital cognitive testing platform, using the Oxford Cognitive Testing Portal, that correlates with serological biomarkers to accurately measure cognitive impairment in Alzheimer's patients. The study highlights the platform's effectiveness in capturing subtle signs of impairment, potentially revolutionizing early diagnosis and tracking of Alzheimer's disease.
By Pooja Toshniwal PahariaAug 28 2023Reviewed by Susha Cheriyedath, M.Sc. In a recent study posted to the medRxiv preprint* server, researchers evaluated the use of the Oxford Cognitive Testing Portal's digital cognitive testing platform for Alzheimer's disease patients and correlated their findings with serological biomarkers of AD.
*Important notice: medRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information. Among Alzheimer's disease patients, digital cognitive testing was used to assess visual short-term memory , visuospatial copying, long-term memory , processing speed, and executive function. The Object-in-Scene Memory Task , Trail Making Test , Oxford Memory Test , a drag-and-drop version of the Rey-Osterrieth Complex Figure , Freestyle Corsi Block Task , and Digit Symbol Substitution Test were among the challenges.
Results As compared to the EHC1 group, Alzheimer's disease patients showed significant impairments in all online cognitive assessments, with large effect sizes and performance correlating with serological biomarkers, particularly pTau181. AD patients had a significant loss in executive functioning, as measured by TMT and DSST, with an average of 8.50 standard deviations below expectation.
The NfL, GFAP, and pTau181 levels were linked with many STM indicators; better cognitive performance was associated with lower levels of serological biomarkers. Likewise, the serological levels were linked to executive function measurements, including TMT and DSST, as well as visuospatial abilities, as measured using ROCF scores. The Aβ42:40 ratio was related to ROCF instant recall scores.
Danmark Seneste Nyt, Danmark Overskrifter
Similar News:Du kan også læse nyheder, der ligner denne, som vi har indsamlet fra andre nyhedskilder.
Time-restricted feeding reverses Alzheimer's symptoms in mice, offers new hope for accessible treatmentResearchers explore the therapeutic potential of circadian-modulating interventions to treat Alzheimer’s disease.
Læs mere »
Scientists create 'hat' that detects Alzheimer's years before first symptomsIt has been hailed a 'fitness tracker for the brain'.
Læs mere »
Revolutionary new bedtime accessory detects Alzheimer's disease while you sleepIt has been hailed a 'fitness tracker for the brain'.
Læs mere »
Influenza and pneumonia vaccinations associated with reduced risk of Alzheimer’s diseaseFlu (influenza) and pneumonia vaccinations are associated with reduced risk of Alzheimer’s disease, according to new research reported at the Alzheimer’s Association International Conference (AAIC) 2020.
Læs mere »
How diet and exercise may rewrite the Alzheimer's script at a molecular levelResearchers explore how lifestyle changes like diet and physical activity can influence microRNA expression in Alzheimer's patients, potentially offering new therapeutic avenues. The study fills a research gap in understanding how such lifestyle modifications could affect molecular mechanisms implicated in Alzheimer’s disease.
Læs mere »
Oxford city centre partially closed after stabbingA 27-year-old man has been taken to hospital with non-life threatening injuries.
Læs mere »